Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Benitec Biopharma Stock Quote

Benitec Biopharma (NASDAQ: BNTC)

$6.82
(42.1%)
$2.02
Price as of April 18, 2024, 4:00 p.m. ET

Benitec Biopharma Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
BNTC +74.42% -98.47% -56.63% -100%
S&P +20.88% +72.88% +11.56% +156%

Benitec Biopharma Company Info

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firms' proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on November 22, 2019 and is headquartered in Hayward, CA.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.